The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

226–250 of 470

  • SevereFDA (Drugs)·D-918-2015·2015-04-29

    Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-595-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clomipramine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clomipramine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clomipramine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-692-2015·2015-04-29

    Attix Pharmaceuticals Recalls Formoterol Fumarate Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Formoterol Fumarate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Formoterol Fumarate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-855-2015·2015-04-29

    Prednisolone Acetate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Prednisolone Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Prednisolone Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-573-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cetirizine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cetirizine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Cetirizine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-957-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zinc Pyrithione Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Zinc Pyrithione active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Zinc Pyrithione active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-605-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cyclobenzaprine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Cyclobenzaprine HCI repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Cyclobenzaprine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-510-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ambroxol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ambroxol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ambroxol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-603-2015·2015-04-29

    Attix Pharmaceuticals Recalls Crotamiton API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Crotamiton active pharmaceutical ingredient due to potential penicillin cross-contamination from shared facility repackaging.

    Product
    Crotamiton active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-646-2015·2015-04-29

    Attix Pharmaceuticals Recalls Duloxetine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Duloxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Duloxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-882-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rivaroxaban API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rivaroxaban active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rivaroxaban active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-577-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chlorobutanol Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chlorobutanol Anhydrous pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chlorobutanol Anhydrous pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-912-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-687-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fluprostenol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fluprostenol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluprostenol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-571-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cephalexin Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling cephalexin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cephalexin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-900-2015·2015-04-29

    Sodium Phenylbutyrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Sodium Phenylbutyrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sodium Phenylbutyrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-700-2015·2015-04-29

    Glipizide API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Glipizide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Glipizide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-836-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pentosan Polysulfate Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pentosan Polysulfate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pentosan Polysulfate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-568-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefixime API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefixime active pharmaceutical ingredient (API) due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cefixime active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-874-2015·2015-04-29

    Attix Pharmaceuticals Recalls Quinine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Quinine Sulfate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Quinine Sulfate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-753-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levalbuterol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levalbuterol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levalbuterol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-513-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aminocaproic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Aminocaproic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aminocaproic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-907-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfathiazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfathiazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Sulfathiazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-754-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levetiracetam Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levetiracetam active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levetiracetam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-787-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methscopolamine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide